Clinical Evidence

Gastroenterology Research and Practice - Hindawi

2016

Background and Objectives. The intestinal mucosa is extremely sensitive to ischemia. Better intestinal preservation is the first step to improve the results of intestinal transplantation. The aim of the study is to investigate the effect of cold Lifor solution on preservation of swine small bowel. Methods. Swine ileum segments (200 cm) were allotransplanted heterotopically after 9-hour cold ...

Jounal - Published by - Gastroenterology Research and Practice: 2016 - Volume 2016, Article ID 3925751, 6 pages

Read More

Establishment of a Transport System for Mouse Epididymal Sperm at Refrigerated Temperatures

2012

In this study, we determined the optimal medium for sperm preservation and evaluated the effect of reduced glutathione in the fertilization medium on sperm fertility after cold storage. We found that higher fertility levels were maintained after 72 ­hour cold storage in the preservation medium Lifor compared with storage in paraffin oil, M2 medium, or CPS­1 medium. This improved protocol provides a simple alternative to transporting live animals or cryopreserved samples for the exchange of genetically engineered mouse strains among research facilities.

Jounal - Published by Cryobiology

Download Now

LiforLab – Solution: A New Oxygen-Enriched Medium for Tumor Tissue transport

2006

In this study, we examined a new physiological, oxygen enriched solution for transport and storage of human tumor samples. Liforlab®solution makes transport of tumor-tissue/biopsies at RT feasible for up to 72h without any impact on viability. Further more, cryo conservation of tumor material and single cell suspensions can be earned out in LS without addition of cryoprotective agents.

Journal - Published by the American Association for Cancer Research

Download Now

Comparison of human umbilical vein endothelial cell cryopreservation

2019

Lifor cryopreservation experiments with human umbilical vein derived endothelial cells (HUVECs) at 0-10% DMSO were compared with Cryostor containing 2, 5 and 10% DMSO.

Abstract

A Novel Method for Generating Xeno - Free Human Feeder Cells for Human Embryonic Stem Cell Culture

2008

In this study we have developed a completely animal-free method to derive HFFs from primary tissues. We demonstrate that animal-free (AF) HFFs do not enter senescence within 55 passages when cultured in animal-free conditions.

Abstract - PubMed.org

Cellular Incorporation into Electrospun nanofibers

2008

Cells can be incorporated into nanofibers with maintained cell viability, ability to proliferate and function.

Abstract - PubMed.org

A Comparative Study of Freezing Cells and Spheroids: Towards a New Model System for Optimizing Freezing Protocols for Cryobanking of Human Tumours

2009

In this study, we examined a new physiological, oxygen enriched solution fortransport and storage of human tumor samples. Liforlab®solution makes transport of tumor-tissue/biopsies at RT feasible for up to 72h without any impact on viability. Furthermore,cryoconservation of tumor material and single cell suspensions can be earned out in LS without addition of cryoprotective agents.

Abstract - PubMed.org

Nonfrozen Transport Medium Preserves and Restores Skeletal Muscle Enzymatic Activity and Morpology

2009

This study aims to investigate the utility of Aedesta™ cell/tissue preservation medium for the non-frozen processing of muscle biopsy specimens. Specifically, the goal is to determine whether this novel, high-oxygen-capacity transport medium adequately preserves fresh tissue for investigation of routine enzyme histochemistry, immunohistochemistry and other methodologies. In this study, we describe a simple and reliable method for preserving and restoring skeletal muscle morphology, immu-nogenicity, and enzyme activity.

Abstract - PubMed.org Download Now

Nonfrozen Transport Medium Preserves and Restores Skeletal Muscle Enzymatic Activity and Morpology

2009

This study aims to investigate the utility of Aedesta™ cell/tissue preservation medium for the non-frozen processing of muscle biopsy specimens. Specifically, the goal is to determine whether this novel, high-oxygen-capacity transport medium adequately preserves fresh tissue for investigation of routine enzyme histochemistry, immunohistochemistry and other methodologies. In this study, we describe a simple and reliable method for preserving and restoring skeletal muscle morphology, immu-nogenicity, and enzyme activity.

Abstract - Published by the journal of Histotechnology

Download Now

Flow Cytometry Analysis of Tissue Viability and Marker Preservation in Vitacor (Detraxi) versus RPMI plus FBS Media

2018

This study aims to investigate the utility of Aedesta™ cell/tissue preservation medium for the non-frozen processing of muscle biopsy specimens. Specifically, the goal is to determine whether this novel, high-oxygen-capacity transport medium adequately preserves fresh tissue for investigation of routine enzyme histochemistry, immunohistochemistry and other methodologies. In this study, we describe a simple and reliable method for preserving and restoring skeletal muscle morphology, immu-nogenicity, and enzyme activity

Abstract

Download Now

Investigations of Motility and fertilization Potential in Thawed Cryopreserved Mouse Sperm from Cold-Stored Epididymides

2014

We demonstarte an improved protocol for cold-storage of epydidymides that can facilitate transport of genectically engineered-mice and preserve sperm viability after cryopreservation.

Abstract - Published by Cryobiology

Download Now

The Influence of Storage Temperature during Machine Perfusion on Preservation quality of Marginal Donor Livers

2010

The aim of his study was to evaluate the influence of oxygen-ated machine perfusion at different temperatures on the organ via-bility after a prolonged time of warm ischemia.

Abstract - Published by Cryobiology

Download Now

Charite Clinic – Oxygenated Machine Perfusion of Non-Heart-Beating Donor Livers at Different Temperatures

2010

Although the use of Non-Heart-Beating Donors has the potential to increase the number of available organs, livers are used only very scarce because of the risk of primary non function. There is evidence that machine perfusion (MP)is able to improve the preservation of marginal organs. The aim of this study was to evaluate the influence of the perfusate temperature during oxygenated MP on graft fucntion. Lifor® organ preservation solution, containing microencapsulated hem as oxygen carrier, has proven to be effective in preserving livers at elevated temperatures.

Abstract - Published by Cryobiology

Download Now

Room Temperature Pulsitile Perfusion of Renal Allografts with Lifor Compared with Hypothermic Machine Pump Solution

2009

This pilot study compared the use of the Lifor Organ Preservation Medium (RTLF) at room temperature with hypothermic Belzer machine preservation solution (CMPS) and room in vitro temperature Belzer machine preservation solution (RTMPS) in a porcine model of uncontrolled donation after cardiac death (DCD) this study demonstrated that room temp with LF OPM results in improved perfusion characteristics and a seemingly blunted inflammatory response.

Abstract - Published by Cryobiology

Download Now

Lake Immunogenics Transfusion Study

2012

The intent of this feasability study was to determine the potential of Lifor as a blood substitute. A Rat model was used to investitage the ability of Lifor to extend life following hemorrage.

Download Now

Lifor Organ Preservation Solution Protects Pulmonary Microvasculature in a Rat Model of Ex Vivo Lung Perfusion and Transplantation

2015

The main objective of this study was to establish a ratmodel to enable the systematic study of EVLP, andto identify organ perfusates to better preserve microvascular function. Our results indicate that Lifor perfusion during EVLP preserved microvascularintegrity ex vivo, and resulted in better in vivo function post transplantation.Maintenance of ZO-1 expression provided a possible explanation for our findings.

Abstract presented at 2015 American Transplant Congress - Published by ASTS May 2-6, 2015 in Philadelphia, Pennsylvania

Download Now

Approach

We believe that Lifor™ is the preservation solution of the future. It was invented with a passion for improving organ and tissue preservation. Through the development of Lifor™, the concept in the forefront of our approach has always been to improve the science and safety of the tissue and grafts. The initial goal was to improve on the other preservation alternatives by providing better nutrients for cell growth and overall improved preservation by nullifying the need to be flushed from the tissue or organ. This original solution was formulated to contain less salts and sugar so not to cause any adverse side effects such as heart or kidney failure when grafting organs. Lifor™ significantly mitigated both warm and cold renal reperfusion injury and affords greater protection from apoptosis.

Over time, Lifor™ has gone through significant testing by leaders in the field of Sperm, Tissue, and Organ Preservation. That testing led to the creation of the second version of Lifor™ where the goal was to eliminate the dangerous agents that cause viral contamination and to tissue by freezing or cryopreserving for short term preservation. The second version of Lifor™ became a true synthetic and removed all human and animal proteins and growth factors to eliminate all harmful and potentially dangerous allergenic and viral causing substances that were used in the name of saving organs.

That brings us to the most current version (that brings us to the most recent patent-pending version of the solution) of Lifor™ currently in production. This product now promotes metabolism over a wide range of temperature gradients including room temperature and prevents organ and tissue damage on a cellular level. It also has the capability to reverse harvesting damage. We continue to push the advancement of Lifor™ and the future is yet to be seen. Testing continues in the fields of Cryopreservation, Flow Cytometry, and Long-Term Tissue Transport and we continue to push the research into new therapeutic areas and applications

Research

At Detraxi, we perform extensive R&D to ensure that the solutions we deliver are reliable and effective – guaranteeing that we provide you with factual information and viable solutions.

Biopreservation

using Lifor™ is already proven to be superior to the established market leading cell culture media, even when the gold standard media is used in conjunction with Fetal Bovine Serum (FBS). Further research will be conducted here to confirm its capability to achieve this without causing any distraction from tissue histology which is critical in most areas of diagnosis and we will also be looking to see if we can further extend the hold times and across a wider temperature range.

Tissue and organ transplantation

is a field that has had little in the way of innovation for close to 30 years and is a harsh, high risk and heavily constrained approach to the re-use of viable tissue and organs. Our technologies contain no preservatives, animal proteins, and does not need to be used at refrigerated temperatures. Lifor™ will significantly extend the hold times between harvesting and grafting. We continue to expand our research into limiting the need to be flushed prior to implantation and further extending the hold times and working temperature gradient. Additional next steps are to progress programs of work to prove capability in the veterinary market.

Regenerative Medicine

has been seen as opening the door to a new generation of treatments that can potentially restore diseased and injured tissues and whole organs. Broadly, the science can be grouped as:

Tissue Engineering and Biomaterials

Biologically compatible scaffolds that can be implanted in the body to form a scaffold for new tissue formation. If the scaffold is in the geometric shape of the tissue that needs to be generated, and the scaffold attracts cells the outcome is new tissue in the shape desired. If the newly forming tissue is subjected to exercise as it forms, the outcome can be new functional engineered issue. To be successful these technologies need advanced media to support growth and we are working on programs to develop our solution technologies to more closely address these requirements.

Cellular Therapies

The usage of stem cells, that are found in every human, have become increasingly utilized in medicine today. Studies have illustrated that if adult stem cells are harvested and then injected at the site of diseased or damaged tissue, reconstruction of the tissue is feasible under the right circumstances. These cells can be collected from blood, fat, bone marrow, dental pulp, skeletal muscle, and other sources. Harvested stem cells are prepared and injected into patients to repair diseased or damaged tissue. The challenges of mechanical cell damage and metabolic demand on thawing are well documented and impact stem cell viability levels. Lifor™ is already proven to meet the needs of a single media across the entire round trip and achieves high levels of cell viability. We continue to conduct research that will improve its protective properties across the Cryogenic field and make it the solution of choice in a progressively regulated area of medicine.

Bioengineered Organs

The future of transplants is using bio-engineered organs, this addresses the issue around quality and antigenic compatibility. The biggest challenge is meeting the needs of a tissue-based organ being developed to support whole organ synthesis. This is a cutting edge area of research and we are excited to work with advance research partners to assess the potential for our technologies to play a part in this new area of medicine.